These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27567629)

  • 41. Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.
    Sandoo A; Dimitroulas T; Toms TE; Hodson J; Veldhuijzen van Zanten JJ; Smith JP; Kitas GD
    Clin Biochem; 2012 Nov; 45(16-17):1399-403. PubMed ID: 22820438
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.
    Berghen N; Teuwen LA; Westhovens R; Verschueren P
    Clin Rheumatol; 2015 Oct; 34(10):1687-95. PubMed ID: 26219489
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvement of fatigue in patients with rheumatoid arthritis treated with biologics: relationship with sleep disorders, depression and clinical efficacy. A prospective, multicentre study.
    Genty M; Combe B; Kostine M; Ardouin E; Morel J; Lukas C
    Clin Exp Rheumatol; 2017; 35(1):85-92. PubMed ID: 27749229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.
    Flendrie M; Vissers WH; Creemers MC; de Jong EM; van de Kerkhof PC; van Riel PL
    Arthritis Res Ther; 2005; 7(3):R666-76. PubMed ID: 15899052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy.
    Erer B; Yilmaz G; Yilmaz FM; Koklu S
    Rheumatol Int; 2009 Apr; 29(6):651-4. PubMed ID: 18953538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis.
    Radovits BJ; Kievit W; Fransen J; van de Laar MA; Jansen TL; van Riel PL; Laan RF
    Ann Rheum Dis; 2009 Sep; 68(9):1470-3. PubMed ID: 19015210
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
    Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
    Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The impact of therapy with TNF-blockers on health-related quality of life in rheumatoid arthritis patients. A pilot study].
    Abalos Medina GM; Ruiz Villaverde G; Sánchez Cano D; Ruiz Villaverde R; Ramírez Rodrigo J; Raya Álvarez E; Villaverde Gutiérrez C
    Reumatol Clin; 2011; 7(3):167-71. PubMed ID: 21794808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.
    Alivernini S; Peluso G; Fedele AL; Tolusso B; Gremese E; Ferraccioli G
    Arthritis Res Ther; 2016 Feb; 18():39. PubMed ID: 26842890
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sleep Quality Is Related to Disease Activity in Patients With Ankylosing Spondylitis: A Polysomnographic Study.
    İn E; Turgut T; Gülkesen A; Yolbaş S; Akgöl G; Koca SS
    J Clin Rheumatol; 2016 Aug; 22(5):248-52. PubMed ID: 27464768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
    Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
    J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutrophils of rheumatoid arthritis patients on anti-TNF-α therapy and in disease remission present reduced adhesive functions in association with decreased circulating neutrophil-attractant chemokine levels.
    Dominical VM; Bértolo MB; Almeida CB; Garrido VT; Miguel LI; Costa FF; Conran N
    Scand J Immunol; 2011 Apr; 73(4):309-18. PubMed ID: 21208248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
    J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis.
    Tikiz H; Arslan O; Pirildar T; Tikiz C; Bayindir P
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):98-103. PubMed ID: 20382605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.